Brief: Guardant Health Q4 Adjusted EPS USD -0.62 Vs. IBES Estimate USD -0.74
20/02/2025 21:05
Feb 20 (Reuters) - Guardant Health Q4 adjusted EBITDA USD -78.4 million vs. IBES estimate USD -63.9 million. * Q4 EPS USD -0.9 * Q4 adjusted net income USD -77.3 million vs. IBES estimate USD -94.3 million * outlook FY revenue USD 850-860 million
Recent news on Guardant Health
See all newsBrief: Guardant Health Announces Approval In Europe Of Guardant360® Cdx
Grail's cancer blood test nears landmark FDA approval, but insurance coverage looms
US Health Secretary Kennedy Jr. adds eight new members to key health committee (updated)
Brief: US FDA Grants Accelerated Approval To Etcamah For Advanced Breast Cancer With ESR1 Mutation
Brief: Guardant Health To Appeal Federal District Court Judgment